Biomolecules and Biomedicine,
Journal Year:
2023,
Volume and Issue:
unknown
Published: Jan. 15, 2023
Cuproptosis,
a
copper-induced
mechanism
of
mitochondrial-related
cell
death,
has
been
implicated
as
breakthrough
in
the
treatment
cancer
and
become
new
strategy.
Furthermore,
long
non-coding
RNA
(lncRNA)
can
change
biological
activities
tumor
cells.
Worldwide,
lung
squamous
carcinoma
(LUSC)
is
among
most
common
annoying
tumors.
LncRNAs
related
to
cuproptosis
are
not
researched
at
LUSC.
Our
research
intends
develop
signature
on
basis
cuproptosis-associated
lncRNAs,
which
predict
LUSC
prognosis
investigate
immunological
features.
The
TCGA
database
was
used
retrieve
transcriptome,
clinical,
gene
mutation
data.
For
statistical
analysis,
we
utilized
R
program.
We
created
consisting
three
cuproptosis-related
lncRNAs
this
investigation
(including
AC002467.1,
LINC01740,
LINC02345).
Survival
analyses
Receiver
Operating
Characteristic
curves
demonstrated
that
possessed
powerful
predictive
capability.
signature’s
ability
confirmed
by
curve
principal
component
analysis.
Notably,
patient
with
high-risk
score
high
burden
level
had
lower
survival
time.
immune
dysfunction
exclusion
analysis
showed
these
individuals
low-risk
scores
may
benefit
from
immunotherapy.
constructed
be
prognostic
markers
It
contributes
immunotherapy
offers
LUSC’s
therapy
direction.
Journal of Oncology,
Journal Year:
2022,
Volume and Issue:
2022, P. 1 - 27
Published: July 6, 2022
Cuproptosis,
a
new
type
of
programmed
cell
death,
is
involved
in
the
development
and
progression
malignancies.
The
study
cuproptosis-associated
long
non-coding
RNAs
(lncRNAs)
soft
tissue
sarcomas
(STSs)
however
limited.
There
also
uncertainty
regarding
prognostic
accuracy
lncRNAs
STSs
their
relationship
to
tumor
immune
microenvironment.
aim
this
was
determine
significance
cuprotosis-associated
Transcriptomic
clinical
data
from
patients
with
were
obtained
through
Cancer
Genome
Atlas
(TCGA).
Overall,
259
randomly
allocated
training
group
or
testing
group.
In
group,
lncRNA
signature
constructed,
verified
On
basis
risk
scores
features,
we
later
developed
hybrid
nomogram.
We
performed
functional
microenvironment
analysis
based
on
signature.
A
5
created.
Based
signature,
categorized
STS
into
high-risk
low-risk
groups.
showed
that
at
high
had
worse
prognosis
than
those
low
risk.
nomogram
then
constructed
combining
characteristics
scores,
it
shown
have
credible
predictive
power.
Functional
enrichment
microenvironmental
analyses
tend
be
immunologically
sensitive
tumors.
our
study,
found
which
serves
as
an
independent
indicator.
Cuproptosis-associated
may
play
role
microenvironment,
might
therapeutic
target
for
STSs.
Biomarker Research,
Journal Year:
2023,
Volume and Issue:
11(1)
Published: Jan. 18, 2023
Abstract
Over
the
past
decade,
targeted
therapy
for
oncogene-driven
NSCLC
and
immune
checkpoint
inhibitors
non-oncogene-driven
NSCLC,
respectively,
have
greatly
improved
survival
quality
of
life
patients
with
unresectable
NSCLC.
Increasingly,
these
biomarker-guided
systemic
therapies
given
before
or
after
surgery
been
used
in
early-stage
In
March
2022,
US
FDA
granted
approval
neoadjuvant
nivolumab
chemotherapy
stage
IB-IIIA
Several
phase
II/III
trials
are
evaluating
clinical
efficacy
various
inhibitor
combinations
molecular
respectively.
However,
application
precision
treatment
requires
a
paradigm
shift
biomarker
testing
multidisciplinary
collaboration
at
diagnosis
this
comprehensive
review,
we
summarize
current
landscape,
recent
advances,
new
challenges
endpoint
selections,
practical
considerations
timely
diagnosis,
perspectives
emerging
resectable,
These
hold
promise
to
improve
surgical
pathological
outcomes,
reduce
recurrences,
guide
postoperative
therapy,
cure
rates
resectable
Journal of Translational Medicine,
Journal Year:
2024,
Volume and Issue:
22(1)
Published: Jan. 23, 2024
Abstract
Idiopathic
pulmonary
fibrosis
(IPF)
is
a
globally
prevalent,
progressive
disease
with
limited
treatment
options
and
poor
prognosis.
Because
of
its
irreversible
progression,
IPF
affects
the
quality
length
life
patients
imposes
significant
burden
on
their
families
social
healthcare
services.
The
use
antifibrotic
drugs
pirfenidone
nintedanib
can
slow
progression
to
some
extent,
but
it
does
not
have
reverse
effect
option
lung
transplantion
also
owing
contraindications
transplantation,
possible
complications
after
risk
death.
Therefore,
discovery
new,
effective
methods
an
urgent
need.
Over
recent
years,
various
studies
been
undertaken
investigate
relationship
between
interstitial
pneumonia
cancer,
suggesting
that
immune
checkpoints
in
are
similar
those
tumors.
Immune
class
immunosuppressive
molecules
essential
for
maintaining
autoimmune
tolerance
regulating
duration
magnitude
responses
peripheral
tissues.
They
prevent
normal
tissues
from
being
damaged
destroyed
by
response.
While
current
focused
PD-1/PD-L1
CTLA-4,
may
be
only
checkpoint
treatment.
This
review
discusses
application
IPF,
aim
finding
new
direction
Journal of Experimental & Clinical Cancer Research,
Journal Year:
2024,
Volume and Issue:
43(1)
Published: May 3, 2024
Mucosal-associated
invariant
T
(MAIT)
cells
have
been
reported
to
regulate
tumor
immunity.
However,
the
immune
characteristics
of
MAIT
in
non-small
cell
lung
cancer
(NSCLC)
and
their
correlation
with
treatment
efficacy
checkpoint
inhibitors
(ICIs)
remain
unclear.
In
this
study,
we
performed
single-cell
RNA
sequencing
(scRNA-seq),
flow
cytometry,
multiplex
immunofluorescence
assays
determine
proportion
CD8+MAIT
patients
metastatic
NSCLC
who
did
not
respond
anti-PD-1
therapy.
Survival
analyses
were
employed
effects
C-X-C
chemokine
receptor
6
(CXCR6)
expression
on
prognosis
advanced
NSCLC.
The
activated
proliferating
significantly
higher
responders-derived
peripheral
blood
mononuclear
(PBMCs)
tissues
before
therapy,
enhanced
cytotoxicity-related
genes
including
CCL4,
KLRG1,
PRF1,
NCR3,
NKG7,
GZMB,
KLRK1.
responders'
tumor-infiltrating
showed
an
upregulated
CXCR6
expression.
Similarly,
CXCR6+CD8+MAIT
from
responders
genes,
such
as
CST7,
GNLY,
PRF1.
Patients
≥15.1%
CD8+T
ratio
≥35.9%
better
progression-free
survival
(PFS)
after
immunotherapy.
role
immunotherapy
was
potentially
mediated
by
classical/non-classical
monocytes
through
CXCL16-CXCR6
axis.
are
a
potential
predictive
biomarker
for
responding
between
sensitivity
may
be
ascribed
high
Frontiers in Oncology,
Journal Year:
2023,
Volume and Issue:
13
Published: Jan. 25, 2023
Lung
cancer
is
one
of
the
leading
causes
cancer-related
death.
mortality
has
decreased
over
past
decade,
which
partly
attributed
to
improved
treatments.
Curative
surgery
for
patients
with
early-stage
lung
standard
care,
but
not
all
surgical
treatments
have
a
good
prognosis.
Adjuvant
and
neoadjuvant
chemotherapy
are
used
improve
prognosis
resectable
cancer.
Immunotherapy,
an
epoch-defining
treatment,
curative
effects,
prognosis,
tolerability
compared
traditional
ordinary
cytotoxic
chemotherapy,
providing
new
hope
non-small
cell
(NSCLC).
Immunotherapy-related
clinical
trials
reported
encouraging
outcomes
in
their
exploration
different
types
perioperative
immunotherapy,
from
immune
checkpoint
inhibitor
(ICI)
monotherapy,
immune-combination
therapy
(chemoimmunotherapy,
immunotherapy
plus
antiangiogenic
therapy,
radiotherapy,
or
concurrent
chemoradiotherapy),
adjuvant
combined
immunotherapy.
Phase
3
studies
such
as
IMpower
010
CheckMate
816
survival
benefits
operable
patients.
This
review
summarizes
up-to-date
analyzes
efficiency
feasibility
therapies
biomarkers
identify
optimal
NSCLC.
Journal of Cancer Research and Therapeutics,
Journal Year:
2023,
Volume and Issue:
19(4), P. 849 - 865
Published: Aug. 1, 2023
ABSTRACT
With
the
addition
of
immunotherapy,
lung
cancer,
one
most
common
cancers
with
high
mortality
rates,
has
broadened
treatment
landscape.
Immune
checkpoint
inhibitors
have
demonstrated
significant
efficacy
in
non-small
cell
cancer
(NSCLC)
and
are
now
used
as
first-line
therapy
for
metastatic
disease,
consolidation
after
radiotherapy
unresectable
locally
advanced
adjuvant
surgical
resection
chemotherapy
resectable
disease.
The
use
neoadjuvant
immunotherapy
patients
early-stage
NSCLC,
however,
is
still
debatable.
We
will
address
several
aspects,
namely
initial
monotherapy,
combination
chemotherapy,
immunotherapy-related
biomarkers,
adverse
effects,
ongoing
randomized
controlled
trials,
current
issues
future
directions
NSCLC
be
discussed
here.
